CAMCEVI 42 mg (leuprorelin) - Prostate cancer

Opinions on drugs - Posted on Jul 24 2025

Reason for request

First listing

Summary of opinion

Favourable opinion for reimbursement:

in the treatment of hormone-dependent advanced prostate cancer;
in the treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Clinical Benefit

Substantial

The clinical benefit of CAMCEVI 42 mg (leuprorelin) prolongedrelease suspension for injection is substantial in the treatment of hormone-dependent advanced prostate cancer, as well as in the treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.